Using STING activators to enhance cancer treatment
Official title: STING Activators as Therapy for Cancer
Funded at Stinginn, LLC · NIH-10709468 · Data updated 2026-11-12
This study is looking at a new way to help your immune system fight aggressive leukemia by using a special treatment that activates a protein called STING, and it’s designed for patients whose leukemia has come back or hasn’t responded to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stinginn, LLC NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project start | September 17, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $993,879 |
| NIH project number | 5R42CA250629-03 |
| Project ID | NIH-10709468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults suffering from relapsed or refractory acute myeloid leukemia or adult lymphocytic leukemia.
✕Less likely to help
Patients with cancers other than the specified leukemias or those who are not eligible for the clinical trial may not benefit from this research.
What this research studies
This research investigates how to stimulate the body's immune system to fight cancer more effectively by activating a protein called STING. The approach focuses on enhancing the generation of anti-cancer T cells through the activation of antigen-presenting cells, which play a crucial role in immune response. The study will involve a small clinical trial for patients with aggressive forms of leukemia, specifically targeting relapsed or refractory acute myeloid leukemia and adult lymphocytic leukemia. Patients will receive treatment that aims to boost their immune response against their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with aggressive leukemias.
How similar studies have gone: Other research has shown promising results with similar immunotherapeutic approaches, indicating potential for success in this area.
Where this research is happening
-
Stinginn, LLC
Miami, United States Active
Researchers
- Principal investigator: Barber, Glen N — Stinginn, LLC
- Study coordinator: Barber, Glen N
Related research
Other NIH-funded projects on the same topics.
-
Developing a vaccine to prevent diseases caused by the Human T Cell Lymphotropic Virus
This study is testing a new vaccine to help prevent and treat serious health issues linked to the HTLV-1 virus, like adult T cell leukemia and a nerve condition called HAM/TSP, and it's for people who might be at risk of getting this virus.
-
New treatments for cancer using human-specific STING activators
This study is looking at a new way to help your immune system fight cancer by using special drugs that can be taken by mouth, making it easier for patients to access treatment and potentially improve how well it works against different types of cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.